NasdaqGS - Delayed Quote USD

ImmunityBio, Inc. (IBRX)

5.49

+0.55

(+11.13%)

At close: April 23 at 4:00 PM EDT

5.49

0.00

(0.00%)

After hours: April 23 at 7:59 PM EDT

Advanced Chart

Loading Chart for IBRX

9/21 12:03 PM

DELL

Previous Close 4.94
Open 6.16
Bid 5.44 x 400
Ask 5.51 x 100
Day's Range 4.84 - 6.19
52 Week Range 1.25 - 6.93
Volume 30,579,691
Avg. Volume 4,659,187
Market Cap (intraday) 3.717B
Beta (5Y Monthly) 0.04
PE Ratio (TTM) --
EPS (TTM) -1.15
Earnings Date May 9, 2024 - May 13, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.00

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

immunitybio.com

628

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

ImmunityBio's bladder cancer therapy wins FDA approval

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

ImmunityBio's bladder cancer therapy wins FDA approval

The US Food and Drug Administration has approved ImmunityBio's (IBRX) bladder cancer therapy, a significant milestone for the company. ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong, joins Market Domination alongside Yahoo Finance's health reporter Anjalee Khemlani to discuss the company's plans following this pivotal approval. Soon-Shiong says that Anktiva will be "the next generation of immuno-therapy." He claims the drug is the first of its kind to "generate complete remission that's completely durable" for 47 months and longer. Soon-Shiong believes the drug will serve as "a backbone" to "checkpoint inhibitors," a class of immunotherapy drugs. He envisions the drug's potential to target cancers regardless of their location within the body, describing it as "an opportunity to use this as a fundamental platform across all tumor types." Soon-Shiong says he, alongside other entities, collectively invested around $400 million in the company when the drug was first rejected. He further notes that additional investments totaling $100 million are forthcoming, stating, "the company is stable in terms of cash capabilities,"— hoping for a commercial launch of Anktiva in May. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

S&P 500

YTD Return

IBRX

9.36%

S&P 500

6.30%

1-Year Return

IBRX

104.85%

S&P 500

22.67%

3-Year Return

IBRX

69.69%

S&P 500

22.63%

5-Year Return

IBRX

399.09%

S&P 500

74.37%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

IBRX

ImmunityBio, Inc.

5.49

+11.13%

Mkt Cap 3.717B

Industry Biotechnology

IOVA

Iovance Biotherapeutics, Inc.

11.86

+4.77%

Mkt Cap 3.313B

Industry Biotechnology

VNDA

Vanda Pharmaceuticals Inc.

4.6300

-3.54%

Mkt Cap 266.399M

Industry Biotechnology

XFOR

X4 Pharmaceuticals, Inc.

1.2300

-9.56%

Mkt Cap 206.564M

Industry Biotechnology

ABEO

Abeona Therapeutics Inc.

3.4100

-53.67%

Mkt Cap 93.281M

Industry Biotechnology

DAWN

Day One Biopharmaceuticals, Inc.

16.64

+8.19%

Mkt Cap 1.454B

Industry Biotechnology

NKGN

NKGen Biotech, Inc.

1.8500

+25.85%

Mkt Cap 42.19M

Industry Biotechnology

BPTH

Bio-Path Holdings, Inc.

2.6850

-8.05%

Mkt Cap 4.203M

Industry Biotechnology

TGTX

TG Therapeutics, Inc.

14.25

+1.06%

Mkt Cap 2.2B

Industry Biotechnology

ANVS

Annovis Bio, Inc.

11.88

+3.39%

Mkt Cap 130.814M

Industry Biotechnology

AKBA

Akebia Therapeutics, Inc.

1.3700

+0.74%

Mkt Cap 286.84M

Industry Biotechnology

Valuation Measures

Annual

As of 4/23/2024

Market Cap

3.72B
Enterprise Value

4.18B
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

4.49k
Price/Book (mrq)

--
Enterprise Value/Revenue

6.72k
Enterprise Value/EBITDA

-9.58

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-52.11%
Return on Equity (ttm)

--
Revenue (ttm)

622k
Net Income Avi to Common (ttm)

-583.2M
Diluted EPS (ttm)

-1.15

Balance Sheet and Cash Flow

Total Cash (mrq)

266.46M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-234.66M

Analyst Price Targets

5.00 Low

5.00 Average

5.49 Current

5.00

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Earnings

Consensus EPS

Fair Value

5.49 Current

Dividend Score

0 Low

IBRX

Sector Avg.

100 High

Hiring Score

0 Low

IBRX

Sector Avg.

100 High

Insider Sentiment Score

0 Low

IBRX

Sector Avg.

100 High

NKTX Nkarta, Inc.

7.56

+2.30%

SANA Sana Biotechnology, Inc.

8.09

+2.02%

BBIO BridgeBio Pharma, Inc.

25.46

+1.56%

IOVA Iovance Biotherapeutics, Inc.

11.86

+4.77%

ALXO ALX Oncology Holdings Inc.

15.50

+8.92%

ALLO Allogene Therapeutics, Inc.

3.3700

-0.88%

AKRO Akero Therapeutics, Inc.

21.00

+1.01%

CCCC C4 Therapeutics, Inc.

6.90

+0.58%

APLS Apellis Pharmaceuticals, Inc.

48.72

+2.27%

ARQT Arcutis Biotherapeutics, Inc.

8.74

-2.24%

GRTS Gritstone bio, Inc.

0.7386

-0.93%

VERV Verve Therapeutics, Inc.

6.88

-0.43%

ROIV Roivant Sciences Ltd.

10.94

+3.21%

AMLX Amylyx Pharmaceuticals, Inc.

1.9500

-1.52%

IMVT Immunovant, Inc.

28.61

-0.45%

MRSN Mersana Therapeutics, Inc.

3.2100

+1.90%

Date
Close
Open
High
Low
Volume

News

Life

Entertainment

Finance

Sports

New on Yahoo

ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

ImmunityBio's bladder cancer therapy wins FDA approval

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

ImmunityBio's bladder cancer therapy wins FDA approval

Profitability and Income Statement

Balance Sheet and Cash Flow